Global Pneumonia Therapeutics Market Overview:
According to SPER Market Research, the Global Pneumonia Therapeutics Market is estimated to reach USD 42.62 billion by 2032 with a CAGR of 8.3%.
An infection that affects the lower respiratory system is pneumonia. Additionally, pneumonia exhibits symptoms including shortness of breath, fever, chest discomfort, nausea, and vomiting. Alveoli, the lungs' air sacs, are filled with fluid or pus in pneumonia, which results in inflammation. It is frequently found in children and the elderly and is mostly brought on by microorganisms including fungi, bacteria, viruses, and parasites. It mainly affects persons with low immune systems.
The increased prevalence of pneumonia is a significant factor driving the expansion of the global market for therapies treating the condition. Additionally, throughout the anticipated period, an increase in the frequency of community-acquired pneumonia is anticipated to fuel market expansion. Additionally, it is anticipated that an increase in product releases following FDA clearance would assist the sector to generate the most income. Additionally, it is anticipated that a rise in clinical trials for the R&D of vaccines and medicinal compounds would support industrial expansion in the next years. The establishment of strict rules for pharmaceuticals and vaccines, however, impedes market expansion.
Impact of COVID-19 on the Global Pneumonia Therapeutics Market
On January 30, 2021, the World Health Organization designated the COVID-19 outbreak a public health emergency of global significance. A person with COVID-19 is especially vulnerable to pneumonia, which can result in wheezing and an accumulation of mucus in the alveoli. This is anticipated to fuel the market for pneumonia treatments. Additionally, it is anticipated that growth in R&D for the treatment of pneumonia associated with COVID-19 would help the market to produce significant revenue throughout the projection period. However, the COVID-19 shortage of workers as well as resource restrictions are anticipated to have a detrimental effect on the industry's growth throughout the projection period. In addition, the industry expansion has been slowed by the installation of strict government restrictions governing lockdown. Additionally, it is urgent to develop fresh products that can aid in the fight against COVID-19. Because of this, the market for pneumonia treatments is expected to produce more money throughout the forecast period.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Access, By Component, By Type, By End User |
| Geographies covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | Atos SE, Alioth LLC, Cardcom Technology, CardLogix Corporation, CPI Card Group, Eastcompeace, Fingerprint Cards AB, Gemalto NV, Giesecke & Devrient, HID Global Corporation, IDEMIA, Infineon Technologies AG., Texas Instruments, Watchdata Technologies.
|
Global Pneumonia Therapeutics Market Segmentation:
By Therapeutics: Based on the Therapeutics, Global Pneumonia Therapeutics Market is segmented as; Prevention Vaccines, Treatment Drugs {Antibacterial Drugs (Macrolide, Quinolones, Aminopenicillins, Macrolides, B-lactamase inhibitors, Cephalosporins, Tetracyclines, Glycopeptide antibiotics, Carbapenems, Others), Antiviral Drugs, Antifungal Drugs}.
By Distribution Channel: Based on the Distribution Channel, Global Pneumonia Therapeutics Market is segmented as; Hospitals, Pharmaceutical Stores, Others.
By Age Group: Based on the Age Group, Global Pneumonia Therapeutics Market is segmented as; Pediatric, Adult and Geriatric.
By Infection Type: Based on the Infection Type, Global Pneumonia Therapeutics Market is segmented as; Hospital-acquired pneumonia, Community-acquired pneumonia, Ventilator-associated pneumonia.
By Region: Due to rising geriatric populations, an ageing population, and an increase in both adult and paediatric multidrug resistance, North America had the largest revenue share and is predicted to keep it throughout the forecast period. These factors reinforce the need for development and rising R&D activities.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Pneumonia Therapeutics Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Pneumonia Therapeutics Market, By Therapeutics, 2019-2032 (USD Million)
6.1 Prevention Vaccines
6.2 Treatment Drugs
6.2.1 Antibacterial Drugs
6.2.1.1 Macrolide
6.2.1.2 Quinolones
6.2.1.3 Aminopenicillins
6.2.1.4 Macrolides
6.2.1.5 B-lactamase inhibitors
6.2.1.6 Cephalosporins
6.2.1.7 Tetracyclines
6.2.1.8 Glycopeptide antibiotics
6.2.1.9 Carbapenems
6.2.1.10 Others
6.2.2 Antiviral Drugs
6.2.3 Antifungal Drugs
7. Global Pneumonia Therapeutics Market, By Distribution Channel, 2019-2032 (USD Million)
7.1 Hospitals
7.2 Pharmaceutical Stores
7.3 Others
8. Global Pneumonia Therapeutics Market, By Age Group, 2019-2032 (USD Million)
8.1 Pediatric
8.2 Adult
8.3 Geriatric
9. Global Pneumonia Therapeutics Market, By Infection Type, 2019-2032 (USD Million)
9.1 Hospital-acquired pneumonia (HAP)
9.2 Community-acquired pneumonia (CAP)
9.3 Ventilator-associated pneumonia (VAP)
10. Global Pneumonia Therapeutics Market, By Region, 2019-2032 (USD Million)
10.1 North America
10.1.1 United States
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 Germany
10.2.2 United Kingdom
10.2.3 France
10.2.4 Italy
10.2.5 Spain
10.2.6 Rest of Europe
10.3 Asia-Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 Australia
10.3.5 South Korea
10.3.6 Rest of Asia-Pacific
10.4 South America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Rest of South America
10.5 Middle East & Africa
10.5.1 Kingdom of Saudi Arabia
10.5.2 United Arab Emirates
10.5.3 Rest of Middle East & Africa
11. Company Profiles
11.1 Abbott Laboratories
11.1.1 Company details
11.1.2 Financial outlook
11.1.3 Product summary
11.1.4 Recent developments
11.2 Bayer AG
11.2.1 Company details
11.2.2 Financial outlook
11.2.3 Product summary
11.2.4 Recent developments
11.3 Eli Lilly & Company
11.3.1 Company details
11.3.2 Financial outlook
11.3.3 Product summary
11.3.4 Recent developments
11.4 Glaxosmithkline Plc.
11.4.1 Company details
11.4.2 Financial outlook
11.4.3 Product summary
11.4.4 Recent developments
11.5 Lupin Pharmaceuticals, Inc.
11.5.1 Company details
11.5.2 Financial outlook
11.5.3 Product summary
11.5.4 Recent developments
11.6 Merck KGAA
11.6.1 Company details
11.6.2 Financial outlook
11.6.3 Product summary
11.6.4 Recent developments
11.7 Novartis AG
11.7.1 Company details
11.7.2 Financial outlook
11.7.3 Product summary
11.7.4 Recent developments
11.8 Pfizer, Inc.
11.8.1 Company details
11.8.2 Financial outlook
11.8.3 Product summary
11.8.4 Recent developments
11.9 Sanofi S.A.
11.9.1 Company details
11.9.2 Financial outlook
11.9.3 Product summary
11.9.4 Recent developments
11.10 Teva Pharmaceuticals Industries Limited
11.10.1 Company details
11.10.2 Financial outlook
11.10.3 Product summary
11.10.4 Recent developments
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
